Accelerate Diagnostics Inc AXDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
-
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
-
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial
-
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results
Trading Information
- Previous Close Price
- $1.82
- Day Range
- $1.78–1.96
- 52-Week Range
- $0.73–7.00
- Bid/Ask
- $1.87 / $2.02
- Market Cap
- $46.17 Mil
- Volume/Avg
- 39,206 / 57,130
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 134
Comparables
Valuation
|
Metric
|
AXDX
|
TIHE
|
137310
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | — | 0.38 |
Price/Sales | 2.93 | — | 1.63 |
Price/Cash Flow | — | — | — |
Price/Earnings
AXDX
TIHE
137310
Financial Strength
|
Metric
|
AXDX
|
TIHE
|
137310
|
|---|---|---|---|
Quick Ratio | 0.90 | 0.00 | 3.91 |
Current Ratio | 1.28 | 0.00 | 5.74 |
Interest Coverage | −3.05 | — | −3.51 |
Quick Ratio
AXDX
TIHE
137310
Profitability
|
Metric
|
AXDX
|
TIHE
|
137310
|
|---|---|---|---|
Return on Assets (Normalized) | −98.11% | — | −3.23% |
Return on Equity (Normalized) | — | — | −4.42% |
Return on Invested Capital (Normalized) | −334.34% | — | −2.74% |
Return on Assets
AXDX
TIHE
137310
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Rbntrvckz | Kxclyd | $196.0 Bil | |||
| Stryker Corp
SYK
| Ktcdktwjj | Wxmc | $133.8 Bil | |||
| Boston Scientific Corp
BSX
| Llrwrgww | Lwnxp | $124.5 Bil | |||
| Medtronic PLC
MDT
| Lzcynxgfd | Lntygw | $113.2 Bil | |||
| Edwards Lifesciences Corp
EW
| Grcvsqtsz | Ksmtb | $39.5 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Cjrqv | Tqbt | $30.2 Bil | |||
| DexCom Inc
DXCM
| Kblqtkrllk | Mtwst | $27.3 Bil | |||
| Steris PLC
STE
| Ldmnxbtfd | Dkvfjbf | $22.8 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Mkgwhqqht | Yqlh | $21.3 Bil | |||
| Insulet Corp
PODD
| Lwcdttngp | Wvgfqx | $16.1 Bil |
United States